+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk Factors and Clinical Significance of Prechoroidal Cleft in Neovascular Age-Related Macular Degeneration



Risk Factors and Clinical Significance of Prechoroidal Cleft in Neovascular Age-Related Macular Degeneration



Retina 37(11): 2047-2055



To investigate the risk factors associated with prechoroidal cleft occurrence after treatment for neovascular age-related macular degeneration (nAMD) and to elucidate its clinical significance. Two hundred thirty-four subjects who were treated for neovascular age-related macular degeneration were assessed to identify prechoroidal cleft on optical coherence tomography. Clinical variables were compared between patients manifesting a cleft (cleft group) and patients who did not (control group). Prechoroidal cleft was detected in 29 of 234 patients (8.1%). Although the baseline visual acuity was not different between the 2 groups, logMAR visual acuity at final visit was 0.89 ± 0.74 (with approximate Snellen equivalent of 20/160) in the cleft group and 0.65 ± 0.69 (with approximate Snellen equivalent of 20/100) in controls (P < 0.05). Within cleft group, the early-onset (<6 months) subgroup had even worse visual outcomes than the late-onset subgroup (P < 0.05). Multiple logistic regression analyses revealed that the incidence of prechoroidal cleft was positively correlated with having received intravitreal gas injection to displace a submacular hemorrhage and a diagnosis of retinal angiomatous proliferation and typical neovascular age-related macular degeneration (P < 0.05). Diagnosis of retinal angiomatous proliferation and typical neovascular age-related macular degeneration, and a submacular hemorrhage treated by pneumatic displacement were the independent risk factors for development of prechoroidal cleft. Eyes with a cleft, especially clefts that develop early, generally had worse prognoses than eyes without clefts.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060210087

Download citation: RISBibTeXText

PMID: 28114175

DOI: 10.1097/iae.0000000000001435


Related references

Clinical risk factors for poor anatomic response to ranibizumab in neovascular age-related macular degeneration. Open Ophthalmology Journal 8: 3-6, 2014

Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration--evaluation in a clinical setting. Bmc Ophthalmology 13: 84, 2013

Incidence and risk factors for macular hemorrhage following intravitreal ranibizumab injection for neovascular age-related macular degeneration. Journal of Ocular Pharmacology and Therapeutics 29(6): 556-559, 2014

Risk factors for neovascular age-related macular degeneration. Archives of Ophthalmology 110(12): 1701-1708, 1992

Nongenetic risk factors for neovascular age-related macular degeneration. Investigative Ophthalmology and Visual Science 55(8): 5228-5232, 2014

Risk Factors for Discontinuation of Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmic Epidemiology 25(2): 176-182, 2018

Incidence and risk factors for neovascular age-related macular degeneration in the fellow eye. Graefe's Archive for Clinical and Experimental Ophthalmology 256(11): 2061-2068, 2018

Comprehensive analysis of CRP, CFH Y402H and environmental risk factors on risk of neovascular age-related macular degeneration. Molecular Vision 14: 1487-1495, 2008

Clarifying some concepts and clinical significance of refractory or recurrent neovascular age-related macular degeneration. Chinese Journal of Ophthalmology 51(11): 804-807, 2015

Anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Comparison of Age-related Macular Degeneration Treatments Trials 5 year outcomes and implication for clinical practice. Clinical and Experimental Ophthalmology 45(4): 333-335, 2017

Assessment of retinal vessel caliber changes in eyes with non-neovascular age-related macular degeneration after progression to neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 254(3): 599-601, 2016

Systemic risk factors associated with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Retina 33(4): 841-845, 2013

Extremely discordant sib-pair study design to determine risk factors for neovascular age-related macular degeneration. Archives of Ophthalmology 122(4): 575-580, 2004

Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration. Acta Ophthalmologica 96(8): 804-811, 2018

Peripheral autofluorescence and clinical findings in neovascular and non-neovascular age-related macular degeneration. Ophthalmology 120(6): 1271-1277, 2013